

Ontario Public Drug Programs

Drug Submission Status

Report for January 2017

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Rosiglitazone	Avandia	rosiglitazone maleate	2 mg	FC tablet	02403366
Apotex Inc.	Apo-Rosiglitazone	Avandia	rosiglitazone maleate	4 mg	FC tablet	02403374
Apotex Inc.	Apo-Rosiglitazone	Avandia	rosiglitazone maleate	8 mg	FC tablet	02403382
Mylan Pharmaceuticals ULC	Mylan-Cinacalcet	Sensipar	cinacalcet HCl	60mg	FC tablet	02434547
Mylan Pharmaceuticals ULC	Mylan-Cinacalcet	Sensipar	cinacalcet HCl	90mg	FC tablet	02434555

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Pharmascience Inc.	Pms-Zolpidem ODT	Sublinox	zolpidem tartrate	5mg	sublingual-orally disintegrating tablet	02436175
Pharmascience Inc.	Pms-Zolpidem ODT	Sublinox	zolpidem tartrate	10mg	sublingual-orally disintegrating tablet	02436183